Table 4.
Multivariable Cox regression analysis for lymph node recurrence-free survival (LNRFS).
| Variable | Entire Cohort (n = 7565) Lymph Node Recurrence-Free Survival (LNRFS) |
Case Control Cohort (n = 1802) Lymph Node Recurrence-Free Survival (LNRFS) |
||||
|---|---|---|---|---|---|---|
| Hazard Ratio HR |
95% CI | p-Value | Hazard Ratio HR |
95% CI | p-Value | |
| Local therapy | <0.001 | 0.013 | ||||
| BCS + RT | 1 | 1 | ||||
| Mastectomy | 2.442 | 1.675–3.560 | 1.517 | 1.092–2.108 | ||
| Age at diagnosis | 0.025 | 0.030 | ||||
| <40 years | 1 | 1 | ||||
| 40–49 years | 1.795 | 0.857–3.762 | 1.758 | 0.576–5.361 | ||
| 50–59 years | 1.143 | 0.539–2.423 | 0.715 | 0.215–2.376 | ||
| 60–69 years | 1.399 | 0.661–2.960 | 0.871 | 0.262–2.890 | ||
| ≥70 years | 0.603 | 0.238–1.526 | 0.286 | 0.058–1.411 | ||
| Tumor stage | 0.006 | 0.331 | ||||
| T1N0 | 1 | 1 | ||||
| T2N0 | 1.754 | 1.130–2.724 | 1.175 | 0.535–2.584 | ||
| T1N1 | 1.274 | 0.749–2.168 | 1.433 | 0.593–3.463 | ||
| T2N1 | 2.300 | 1.383–3.825 | 2.186 | 0.931–5.134 | ||
| Resection status | 0.366 | |||||
| R0 | 1 | 1 | ||||
| R1/R2 | 0.403 | 0.056–2.888 | NA * | |||
| Grade | <0.001 | 0.082 | ||||
| G1 | 1 | 1 | ||||
| G2 | 1.451 | 0.755–2.787 | 1.121 | 0.327–3.840 | ||
| G3 | 3.651 | 1.841–7.242 | 2.284 | 0.623–8.371 | ||
| Hormone receptor | 0.120 | 0.973 | ||||
| positive | 1 | 1 | ||||
| negative | 1.523 | 0.897–2.586 | 0.982 | 0.342–2.819 | ||
| Chemotherapy | 0.221 | 0.593 | ||||
| yes | 1 | 1 | ||||
| no | 1.303 | 0.853–1.990 | 1.223 | 0.585–2.557 | ||
| Endocrine therapy | 0.193 | 0.702 | ||||
| yes | 1 | 1 | ||||
| no | 0.770 | 0.520–1.141 | 0.885 | 0.475–1.652 | ||
* NA: not applicable, HR not estimable because no event in the R1/2 group.